{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:07:49Z","timestamp":1760144869448,"version":"build-2065373602"},"reference-count":37,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Portuguese Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia\/Minist\u00e9rio da Educa\u00e7\u00e3o e Ci\u00eancia (MEC)","award":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"],"award-info":[{"award-number":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"]}]},{"name":"FEDER funds through the Operational Programme for Competitiveness Factors (COMPETE 2020), Programa Operacional de Competitividade e Internacionaliza\u00e7\u00e3o (POCI)","award":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"],"award-info":[{"award-number":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"]}]},{"name":"Rede Nacional de RMN","award":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"],"award-info":[{"award-number":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"]}]},{"name":"PhD","award":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"],"award-info":[{"award-number":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"]}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"],"award-info":[{"award-number":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Regional Development Fund","award":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"],"award-info":[{"award-number":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"]}]},{"name":"Portuguese FCT","award":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"],"award-info":[{"award-number":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"]}]},{"name":"Olle Engkvist Foundation","award":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"],"award-info":[{"award-number":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"]}]},{"name":"Swedish Research Council","award":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"],"award-info":[{"award-number":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"]}]},{"name":"CCDR-N","award":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"],"award-info":[{"award-number":["UID\/QUI\/00686\/2020","UID\/QUI\/00686\/2018","POCI-01-0145-FEDER-031354","PINFRA\/22161\/2016","SFRH\/BD\/85937\/2012","ED431C 2022\/20","SFRH\/BPD\/26106\/2005","219-0154","2021-4186","NORTE-01\u20140145-FEDER-085468"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>A set of 2-aryl-9-H or methyl-6-morpholinopurine derivatives were synthesized and assayed through radioligand binding tests at human A1, A2A, A2B, and A3 adenosine receptor subtypes. Eleven purines showed potent antagonism at A1, A3, dual A1\/A2A, A1\/A2B, or A1\/A3 adenosine receptors. Additionally, three compounds showed high affinity without selectivity for any specific adenosine receptor. The structure-activity relationships were made for this group of new compounds. The 9-methylpurine derivatives were generally less potent but more selective, and the 9H-purine derivatives were more potent but less selective. These compounds can be an important source of new biochemical tools and\/or pharmacological drugs.<\/jats:p>","DOI":"10.3390\/molecules29112543","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T07:38:39Z","timestamp":1716881919000},"page":"2543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives"],"prefix":"10.3390","volume":"29","author":[{"given":"Filipe","family":"Areias","sequence":"first","affiliation":[{"name":"Centre of Chemistry of University of Minho (CQUM), Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal"},{"name":"Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, Avda de Barcelona, E-15782 Santiago de Compostela, Spain"},{"name":"School of Chemical Sciences & Engineering, Yachay Tech University, Yachay City of Knowledge, Urcuqui 100119, Ecuador"}]},{"given":"Carla","family":"Correia","sequence":"additional","affiliation":[{"name":"Centre of Chemistry of University of Minho (CQUM), Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal"}]},{"given":"Ashly","family":"Rocha","sequence":"additional","affiliation":[{"name":"Centre of Chemistry of University of Minho (CQUM), Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-0975","authenticated-orcid":false,"given":"Sofia","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Centre of Chemistry of University of Minho (CQUM), Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4732-1966","authenticated-orcid":false,"given":"Mari\u00e1n","family":"Castro","sequence":"additional","affiliation":[{"name":"Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, Avda de Barcelona, E-15782 Santiago de Compostela, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (IDIS), Traves\u00eda da Choupana s\/n, E-15706 Santiago de Compostela, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5523-1979","authenticated-orcid":false,"given":"Jose","family":"Brea","sequence":"additional","affiliation":[{"name":"Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, Avda de Barcelona, E-15782 Santiago de Compostela, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (IDIS), Traves\u00eda da Choupana s\/n, E-15706 Santiago de Compostela, Spain"}]},{"given":"Huabin","family":"Hu","sequence":"additional","affiliation":[{"name":"Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, SE-75124 Uppsala, Sweden"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-2977","authenticated-orcid":false,"given":"Jens","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, SE-75124 Uppsala, Sweden"}]},{"given":"Maria I.","family":"Loza","sequence":"additional","affiliation":[{"name":"Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, Avda de Barcelona, E-15782 Santiago de Compostela, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (IDIS), Traves\u00eda da Choupana s\/n, E-15706 Santiago de Compostela, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-1949","authenticated-orcid":false,"given":"M. Fernanda","family":"Proen\u00e7a","sequence":"additional","affiliation":[{"name":"Centre of Chemistry of University of Minho (CQUM), Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal"}]},{"given":"M. Alice","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Centre of Chemistry of University of Minho (CQUM), Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s43094-021-00353-w","article-title":"Adenosine: A partially discovered medicinal agent","volume":"7","author":"Batra","year":"2021","journal-title":"Future J. Pharm. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: The state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.2174\/1381612825666190716112319","article-title":"Therapeutic potential of agonists and antagonists of A1, A2a, A2b and A3 adenosine receptors","volume":"25","author":"Jamwal","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Effendi, W.I., Nagano, T., Kobayashi, K., and Nishimura, Y. (2020). Focusing on adenosine receptors as a potential targeted therapy in human diseases. Cells, 9.","DOI":"10.3390\/cells9030785"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/pharmrev.121.000445","article-title":"International union of basic and clinical pharmacology. CXII: Adenosine receptors: A further updates","volume":"74","author":"Ijzerman","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbamem.2010.12.017","article-title":"Recent developments in adenosine receptor ligands and their potential as novel drugs","volume":"1808","author":"Jacobson","year":"2011","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.2174\/1381612825666190716111245","article-title":"P1 receptor agonists\/antagonists in clinical trials-potential drug candidates of the future","volume":"25","author":"Borah","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Borea, P., Varani, K., Gessi, S., Merighi, S., and Vincenzi, F. (2018). The Adenosine Receptors, Springer International Publishing.","DOI":"10.1007\/978-3-319-90808-3"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Stockwell, J., Jakova, E., and Cayabyab, F. (2017). Adenosine A1 and A2A Receptors in the brain: Current research and their role in neurodegeneration. Molecules, 22.","DOI":"10.3390\/molecules22040676"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.23876\/j.krcp.22.011","article-title":"Adenosine receptors as emerging therapeutic targets for diabetic kidney disease","volume":"41","author":"Pak","year":"2022","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_11","first-page":"4784","article-title":"PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: A Phase-IIa trial","volume":"56","author":"Brienza","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1184360","DOI":"10.3389\/fendo.2023.1184360","article-title":"Small molecule allosteric modulation of the adenosine A1 receptor","volume":"14","author":"Nguyen","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1574892812666171108115959","article-title":"Adenosine receptor ligands on cancer therapy: A review of patent literature","volume":"13","author":"Sousa","year":"2018","journal-title":"Recent Pat. Anticancer. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.21873\/invivo.12944","article-title":"A selective adenosine A3 receptor antagonist, HL3501, has therapeutic potential in preclinical liver and renal fibrosis models","volume":"36","author":"Kim","year":"2022","journal-title":"Vivo"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Borea, P.A. (2010). A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics, Springer Science+Business Media B.V.","DOI":"10.1007\/978-90-481-3144-0"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Spinaci, A., Buccioni, M., Dal Ben, D., Maggi, F., Marucci, G., Francucci, B., Santoni, G., Lambertucci, C., and Volpini, R. (2022). A3 adenosine receptor antagonists with nucleoside structures and their anticancer activity. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020164"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/med.21456","article-title":"A3 adenosine receptors as modulators of inflammation: From medicinal chemistry to therapy","volume":"38","author":"Jacobson","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00044-021-02704-x","article-title":"Adenosine receptors as promising targets for the management of ocular diseases","volume":"30","author":"Spinozzi","year":"2021","journal-title":"Med. Chem. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1167\/tvst.11.2.30","article-title":"HL3501, a novel selective A3 adenosine receptor antagonist, lowers intraocular pressure (IOP) in animal glaucoma models","volume":"11","author":"Kim","year":"2022","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20781","DOI":"10.1038\/s41598-020-74521-y","article-title":"Pharmacological characterisation of novel adenosine A3 receptor antagonists","volume":"10","author":"Barkan","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/13543776.2019.1653279","article-title":"Novel therapies for glaucoma: A patent review (2013\u20132019)","volume":"29","author":"Guglielmi","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_22","unstructured":"Lee, J., Kim, S., Kim, D., Ahn, K.H., Lee, G.B., Kim, D., and Hwang, H.S. (2017). Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof. (WO2017123058A1)."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1021\/acs.jmedchem.5b00074","article-title":"5\u2032-C-ethyl-tetrazolyl-N 6-substituted adenosine and 2-chloro-adenosine derivatives as highly potent dual acting A1 adenosine receptor agonists and A3 adenosine receptor antagonists","volume":"58","author":"Petrelli","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"111879","DOI":"10.1016\/j.ejmech.2019.111879","article-title":"Substituted 4-phenylthiazoles: Development of potent and selective A1, A3 and dual A1\/A3 adenosine receptor antagonists","volume":"186","author":"Abdelrahman","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure","volume":"363","author":"Massie","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/11594680-000000000-00000","article-title":"The safety of an adenosine A1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment","volume":"35","author":"Teerlink","year":"2012","journal-title":"Drug Saf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCHEARTFAILURE.108.798389","article-title":"Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure","volume":"2","author":"Mitrovic","year":"2009","journal-title":"Circ. Hear. Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1016\/j.bmc.2019.06.034","article-title":"2-Aryladenine derivatives as a potent scaffold for A1, A3 and dual A1\/A3 adenosine receptor antagonists: Synthesis and structure-activity relationships","volume":"27","author":"Areias","year":"2019","journal-title":"Bioorganic Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1039\/P19900001705","article-title":"Synthesis of 5-amino-4-(cyanoformimidoyl)-1H-imidazole: A reactive intermediate for the synthesis of 6-carbamoyl-1,2-dihydropurines and 6-carbamoylpurines","volume":"1","author":"Alves","year":"1990","journal-title":"J. Chem. Soc. Perkin Trans. 1"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1016\/j.tet.2009.06.065","article-title":"Synthesis and in vitro activity of 6-amino-2,9-diarylpurines for Mycobacterium tuberculosis","volume":"65","author":"Correia","year":"2009","journal-title":"Tetrahedron"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wilson, C.N., and Mustafa, S.J. (2009). Adenosine Receptors in Health and Disease, Springer.","DOI":"10.1007\/978-3-540-89615-9"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/13543776.2013.799142","article-title":"Adenosine A 1 modulators: A patent update (2008 to present)","volume":"23","author":"Giorgi","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1021\/jm100971t","article-title":"In vivo characterization of a dual adenosine A2A\/A1 receptor antagonist in animal models of Parkinson\u2019s disease","volume":"53","author":"Shook","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Jung, J., Lee, Y., Moon, A.-N., Ann, J., Jeong, J.J., Do, N., and Lee, J. (2022). Discovery of Novel Dual Adenosine A2A and A1 receptor antagonists with 1H-Pyrazolo[3,4-d]pyrimidin-6-amine core scaffold as anti-Parkinson\u2019s disease agents. Pharmaceuticals, 15.","DOI":"10.3390\/ph15080922"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.cell.2017.01.042","article-title":"Structure of the adenosine A1 receptor reveals the basis for subtype selectivity","volume":"168","author":"Glukhova","year":"2017","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1111\/bph.15103","article-title":"Adenosine A 2A receptor antagonists: From caffeine to selective non-xanthines","volume":"179","author":"Jacobson","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/0165-6147(93)90080-4","article-title":"Further concerns over Cheng-Prusoff analysis","volume":"14","author":"Leff","year":"1993","journal-title":"Trends Pharmacol. Sci."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/11\/2543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:49:35Z","timestamp":1760107775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/11\/2543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["molecules29112543"],"URL":"https:\/\/doi.org\/10.3390\/molecules29112543","relation":{},"ISSN":["1420-3049"],"issn-type":[{"type":"electronic","value":"1420-3049"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}